Bixiye
QP96-18 Clarification Regarding the use of PLUTO for Minnesota Health Care Program Subscribers Effective December 1, 2018
Taariikhda uu dhaqangalayo Barnaamijka: Nov 14, 2018
Natiijooyinka Raadinta
Soo bandhiga 2331 - 2340 ee natiijooyinka 4234
Bixiye
QP81-18 Changes to Cotiviti Mailroom Operations Center Location
Taariikhda uu Dhaqangalayo Barnaamijka: Sep 25, 2018
Bixiye
QP78-18 Pharmacy Update - Change in Coverage for Brand Serevent Diskus 50 mcg/dose
Taariikhda uu Dhaqangalayo Barnaamijka: Sep 11, 2018
Bixiye
QP71-18 Pharmacy Benefit Update - New Drug-Related Step Therapy with Quantity Limit Criteria: Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors
Taariikhda barnaamijka Dhaqangalayso Agosto 21, 2018
Bixiye
QP90-18 Addition of Drugs to the Self-Administered Oncology Agents Prior Authorization with Quantity Limit Program
Taariikhda uu dhaqangalayo Barnaamijka: Nov 14, 2018
Bixiye
QP69-18 Universal Pharmacy Policy for Minnesota Health Care Programs Subscribers - Morphine Equivalent Dose (MED) Limit Update
Taariikhda barnaamijka Dhaqangalayso Agosto 21, 2018
Bixiye
QP75-18 2018 Blue Cross Blue Shield MHCP Migration and New Initiatives Training
Taariikhda uu Dhaqangalayo Barnaamijka: Sep 07, 2018
Bixiye
QP93-18 Technical Issues with Authorization and Referral Tool on Availity Resolved
Taariikhda uu dhaqangalayo Barnaamijka: Nov 14, 2018
Bixiye
QP79-18 Addition of Drug to the Hereditary Angioedema Prior Authorization with Quantity Limit Program
Taariikhda uu Dhaqangalayo Barnaamijka: Sep 21, 2018
Bixiye
QP77-18 Pharmacy Benefit Exclusion for Onpattro (patisiran) Lipid Complex Intravenous (IV) Injection
Taariikhda uu Dhaqangalayo Barnaamijka: Sep 11, 2018